JPMorgan raised the firm’s price target on Protagonist Therapeutics (PTGX) to $57 from $53 and keeps an Overweight rating on the shares. The pivotal Phase 3 VERIFY data “was a strong showcase” for rusfertide’s potential in polycythemia vera, the analyst tells investors in a research note. The firm says the outcome fell between its base case and “blue sky scenario.” JPMorgan increase its probability of success for rusfertide to 90% from 70%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics: Positive VERIFY Trial Results and Promising Financial Prospects Justify Buy Rating
- Protagonist Therapeutics price target raised to $73 from $67 at BTIG
- Protagonist Therapeutics’ Rusfertide: A Promising Blockbuster in the Polycythemia Vera Market with Strong Buy Rating
- Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Phase 3 Success and Market Potential
- Protagonist Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Results and Robust Financial Outlook